Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (21418)	9/22/2006 5:43:24 PM
From: Ploni	Read Replies (2) \| Respond to of 52153

[I don't know squat about drug development, so pardon my ignorance.] "NX473 did not meet the differentiated profile required by AstraZeneca, particularly in overcoming platinum resistance in ovarian and lung cancer patients who have previously failed a platinum based therapy." So why is PARD looking at it again for platinum-resistant lung cancer patients? (I can understand them looking at it for colorectal and prostate cancers, since AstraZeneca didn't reject it for those applications.) Also, why the focus on determining whether it will help platinum-resistant patients? If it's effective in helping platinum-sensitive patients and can do so with only minor neuropathy, wouldn't that make it a very useful drug?